Lacutamab KOL Event Clinical perspectives and Commercial outlook New-York, October 28th, 2025 Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expr ...

ANALYSIS: Are Prediction Markets Turning Brokers Into Bookies? Regeneron stock jumped on Tuesday after the biotech company reported adjusted earnings of $11.83 per share on $3.75 billion in third-quarter sales. Analysts polled by FactSet expected Regeneron Pharmaceuticals (REGN) to earn $9.65 a share and report $3.59 billion in sales. Notably, third-quarter earnings took a 68-cent hit thanks to a tax charge, and still came in well above forecasts. YOU MAY ALSO LIKE: GSK Crumbles As Blood Cancer Comeback Fa ...

ANALYSIS: Are Prediction Markets Turning Brokers Into Bookies? Incyte (INCY) stock fell on Tuesday after the biotech company reported adjusted earnings of $2.26 per share on $1.37 billion in third-quarter sales. Analysts polled by FactSet expected Incyte to earn $1.58 a share and report $1.25 billion in sales. During the year-earlier period, the company earned $1.07 per share on $1.14 billion in sales. In premarket trades on today's stock market, Incyte stock edged down 1.7% to 91.50. More to follow. Follo ...

Oct 28, 2025 8:49 AM Eastern Daylight Time Lantern Pharma Presents LP-284 Clinical Data at 25 LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. Share DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development, today announced the presentation of clinical da ...

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the company's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for the positive statements made about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no cost or obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois. The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month topline dat ...

-- Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration of PCRX-201 -- BRISBANE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced updated three-year results and a new subset analyses demonstrating sustained efficacy and safety across all patient subgroups, including ...

SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing our publications. We expect to share this data at the upcoming World HUPO confer ...

SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences. Details are as follows: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: November 11, 2025Time: 8:00 AM ETFormat: Fireside Chat Event: Jefferies London Healthcare Conference Date: November 1 ...

GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65 percent) of respondents agree the likelihood of a biological attack on U.S. soil is rising, yet almost half (45 percent) believe the U.S. is unprepared for a biological attack. Conducted by Penta Group on behalf of Emergent, the survey amplifies findings in the unclassified 2025 Annual Thre ...